uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
The cost-effectiveness of growth hormone replacement therapy (Genotropin®) in hypopituitary adults in Sweden
Department of Economics, Centre for Health Economics, University of Gothenburg, Sweden.
Pfizer AB, Sollentuna, Stockholm, Sweden.
Pfizer, Endocrine Care, Pfizer Inc, Sollentuna, Sweden . (Barnendokrinologisk forskning/Gustafsson)
Pfizer Ltd, Walton Oaks, UK.
Show others and affiliations
2013 (English)In: Cost Effectiveness and Resource Allocation, ISSN 1478-7547, Vol. 11, no 1, 24- p.Article in journal (Refereed) Published
Abstract [en]


To evaluate the cost-effectiveness of growth hormone (GH) treatment (Genotropin(R)) compared with no GH treatment in adults with GH deficiency in a Swedish societal setting.


A Markov-type cost-utility simulation model was constructed and used to simulate, for men and women, morbidity and mortality for GH-treated and -untreated individuals over a 20-year period. The calculations were performed using current available prices concerning morbidity-related healthcare costs and costs for Genotropin(R). All costs and treatment effects were discounted at 3%. Costs were expressed in Euro (1[euro sign] = 9.03 SEK). GH-treated Swedish patients (n = 434) were identified from the KIMS database (Pfizer International Metabolic Database) and untreated patients (n = 2135) from the Swedish Cancer Registry and the Hospital Discharge Registry.


The results are reported as incremental cost per quality-adjusted life year (QALY) gained, including both direct and indirect costs for GH-treated versus untreated patients. The weighted sum of all subgroup incremental cost per QALY was [euro sign]15,975 and [euro sign]20,241 for men and women, respectively. Including indirect cost resulted in lower cost per QALY gained: [euro sign]11,173 and [euro sign]10,753 for men and women, respectively. Key drivers of the results were improvement in quality of life, increased survival, and intervention cost.


The incremental cost per QALY gained is moderate when compared with informal thresholds applied in Sweden. The simulations suggest that GH-treatment is cost-effective for both men and women at the [euro sign]55,371 (SEK 500,000 -- the informal Swedish cost-effectiveness threshold) per QALY threshold.

Place, publisher, year, edition, pages
2013. Vol. 11, no 1, 24- p.
National Category
Medical and Health Sciences
URN: urn:nbn:se:uu:diva-209687DOI: 10.1186/1478-7547-11-24PubMedID: 24079522OAI: oai:DiVA.org:uu-209687DiVA: diva2:659075
Available from: 2013-10-24 Created: 2013-10-24 Last updated: 2014-04-09Bibliographically approved

Open Access in DiVA

fulltext(451 kB)52 downloads
File information
File name FULLTEXT01.pdfFile size 451 kBChecksum SHA-512
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Koltowska-Häggström, MariaJonsson, Björn
By organisation
Department of Women's and Children's Health
In the same journal
Cost Effectiveness and Resource Allocation
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
Total: 52 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 326 hits
ReferencesLink to record
Permanent link

Direct link